Echo Therapeutics (ECTE) 2.16 $ECTE
Echo Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Regulatory and Product Development Update
PR Newswire - Fri May 09, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended March 31, 2014. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
Echo Therapeutics Schedules First Quarter 2014 Financial Results and Regulatory and Product Development Update for Friday, May 9, 2014
PR Newswire - Thu May 08, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release its financial results for the quarter ended March 31, 2013 and provide a regulatory and product development update on Friday, May 9, 2014. Management will hold a conference call to review the company's first quarter 2014 performance and provide shareholders with a regulatory and product development update starting at 9:00 a.m. EDT on the same day.
Echo Therapeutics Mails Letter To Stockholders; Urges Stockholders Not To Vote Platinum's Gold Proxy Card
PR Newswire - Tue Apr 29, 3:35PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has mailed the following letter to stockholders in connection with the proxy contest that has been threatened at Echo's 2014 Annual Meeting of Stockholders by a dissident stockholder group led by Platinum Management (NY) LLC:
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Echo Therapeutics Files Preliminary Proxy Materials In Connection With 2014 Annual Meeting Of Stockholders
PR Newswire - Thu Apr 24, 10:45AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has filed revised proxy materials with the Securities and Exchange Commission (SEC) in connection with Echo's 2014 Annual Meeting of Stockholders, including a preliminary form of a revised proxy statement and a preliminary form of a revised WHITE proxy card.
Echo Therapeutics Comments on Proxy Contest by Platinum Management (NY) LLC
PR Newswire - Tue Apr 22, 4:30PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today commented on the recent proxy statement filings made with the Securities and Exchange Commission (SEC) by Platinum Management (NY) LLC confirming that it intends to conduct a proxy contest in connection with Echo's 2014 Annual Meeting of Stockholders and will solicit proxies for the election to the Echo Board of Directors of a candidate in opposition to one of the candidates recommended for election by the Echo Board. Platinum is currently represented on the five-member Echo Board of Directors by its designee Michael M. Goldberg.
Platinum Management (NY) LLC Issues Letter To Stockholders Of Echo Therapeutics, Inc.
PR Newswire - Mon Apr 21, 9:36AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) owning approximately 19.9% of the common stock, issued a letter to fellow stockholders of Echo urging them not to vote the Company's white proxy card and to wait to receive Platinum's proxy statement and GOLD proxy card before voting at the Annual Meeting. When stockholders vote the GOLD proxy card, they will have the opportunity to vote for Platinum's nominee and ALL of the Company's nominees OTHER THAN current director and interim CEO Robert F. Doman, who Platinum opposes.
Echo Therapeutics Slips to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 07, 1:50PM CDT
Echo Therapeutics' fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents.
Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.
Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors.
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference
PR Newswire - Thu Feb 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Echo's Executive Chairman and Interim CEO, will participate in the Leerink Swann 2014 Global Healthcare Conference in New York, New York.
Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
Echo Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Regulatory and Product Development Update
PR Newswire - Fri May 09, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended March 31, 2014. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
Echo Therapeutics Schedules First Quarter 2014 Financial Results and Regulatory and Product Development Update for Friday, May 9, 2014
PR Newswire - Thu May 08, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release its financial results for the quarter ended March 31, 2013 and provide a regulatory and product development update on Friday, May 9, 2014. Management will hold a conference call to review the company's first quarter 2014 performance and provide shareholders with a regulatory and product development update starting at 9:00 a.m. EDT on the same day.
Echo Therapeutics Mails Letter To Stockholders; Urges Stockholders Not To Vote Platinum's Gold Proxy Card
PR Newswire - Tue Apr 29, 3:35PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has mailed the following letter to stockholders in connection with the proxy contest that has been threatened at Echo's 2014 Annual Meeting of Stockholders by a dissident stockholder group led by Platinum Management (NY) LLC:
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Echo Therapeutics Files Preliminary Proxy Materials In Connection With 2014 Annual Meeting Of Stockholders
PR Newswire - Thu Apr 24, 10:45AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has filed revised proxy materials with the Securities and Exchange Commission (SEC) in connection with Echo's 2014 Annual Meeting of Stockholders, including a preliminary form of a revised proxy statement and a preliminary form of a revised WHITE proxy card.
Echo Therapeutics Comments on Proxy Contest by Platinum Management (NY) LLC
PR Newswire - Tue Apr 22, 4:30PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today commented on the recent proxy statement filings made with the Securities and Exchange Commission (SEC) by Platinum Management (NY) LLC confirming that it intends to conduct a proxy contest in connection with Echo's 2014 Annual Meeting of Stockholders and will solicit proxies for the election to the Echo Board of Directors of a candidate in opposition to one of the candidates recommended for election by the Echo Board. Platinum is currently represented on the five-member Echo Board of Directors by its designee Michael M. Goldberg.
Platinum Management (NY) LLC Issues Letter To Stockholders Of Echo Therapeutics, Inc.
PR Newswire - Mon Apr 21, 9:36AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) owning approximately 19.9% of the common stock, issued a letter to fellow stockholders of Echo urging them not to vote the Company's white proxy card and to wait to receive Platinum's proxy statement and GOLD proxy card before voting at the Annual Meeting. When stockholders vote the GOLD proxy card, they will have the opportunity to vote for Platinum's nominee and ALL of the Company's nominees OTHER THAN current director and interim CEO Robert F. Doman, who Platinum opposes.
Echo Therapeutics Slips to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 07, 1:50PM CDT
Echo Therapeutics' fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents.
Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium. Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference. Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors. Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference
PR Newswire - Thu Feb 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Echo's Executive Chairman and Interim CEO, will participate in the Leerink Swann 2014 Global Healthcare Conference in New York, New York. Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
